Abstract 5524
Background
The widespread introduction of ICIs in patients (pts) with metastatic disease has significantly improved outcomes. However, ICIs in the elderly requires further evaluation to determine whether outcomes differ from that observed in younger cohorts. The goal of this study is to utilize real-world data from the Canadian Melanoma Research Network Registry.
Methods
This retrospective observational study was performed in metastatic pts entered into a common clinical registry and who received ipilimumab alone (ipi) and nivolumab (nivo) or pembrolizumab (pembro) from 2008 to February 2019. Demographics, extent of disease, all treatments and adverse events (AEs) were compiled. Comparisons between pts in different age cohorts were made. The potential impact of known prognostic factors was investigated using Cox proportional multivariate analyses.
Results
144 pts over 70 were treated with ICI as 1st line. 43 patients received ipi and 101 received nivo or pembro. BRAF mutation was present in 17%. Pulmonary mets: 56%; Liver mets 34%; Brain mets: 16%. For those aged 70-99, median survival was 10 M (range: 1 M - 50 M). In a comparative cohort of pts aged 50-69, the median survival was 11.8 M (range: 1 M – 78 M). On multivariate analysis age, baseline LDH and BRAF status did not impact overall survival. Within the elderly cohort, the use of ipi was associated with significantly decreased overall survival when compared to nivo and pembro (OS ipi: 6.8 M vs anti-PD1: 10.6 M). 95 pts over 70 received ICIs as 2nd line, with a median survival of 6.3 M, which was not significantly different from the younger cohort who received second-line ICIs (median survival of 8 M). In the elderly cohort, 124 >grade 2 AEs were observed: Rash 25%; Colitis: 18%; Fatigue: 8%; Asthenia: 7%.
Conclusions
ICIs can be effectively utilized in pts over 70. Survival appears to be comparable to that achieved in younger cohorts. Elderly pts who only received ipi appeared to have a worse outcome than those pts who received nivo or pembro.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Global Melanoma Research Network.
Funding
Global Melanoma Research Network.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5007 - Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy
Presenter: Miren Zuazo
Session: Poster Display session 3
Resources:
Abstract
5760 - Landscape of PD-L1 expression status in Chinese solid tumor patients.
Presenter: Yi Zhong
Session: Poster Display session 3
Resources:
Abstract
3733 - Anti-cancer and immunomodulatory effects of cobimetinib in triple negative breast cancer
Presenter: Chun-Yu Liu
Session: Poster Display session 3
Resources:
Abstract
4426 - Differential expression of immunoregulatory molecules and highly-associated cancer genes may provide novel insights into strategic trial design for therapeutics
Presenter: Jacob Adashek
Session: Poster Display session 3
Resources:
Abstract
2752 - Insights into the Tumor Immune Microenvironment using Tissue Phenomics to Drive Cancer Immunotherapy
Presenter: Martin Groher
Session: Poster Display session 3
Resources:
Abstract
5713 - Immune competent somatic mosaic model of colorectal cancer
Presenter: Stefania Napolitano
Session: Poster Display session 3
Resources:
Abstract
1898 - Genomic correlates of response to anti-PDL1 Atezolizumab in non-small-cell lung cancer OAK and POPLAR trials
Presenter: Hari Singhal
Session: Poster Display session 3
Resources:
Abstract
3246 - Erdafitinib (erda) versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
3311 - High level of activity of Nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program
Presenter: Christophe Tournigand
Session: Poster Display session 3
Resources:
Abstract
2314 - TP53 and ATM Co-mutation Predicts Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Presenter: Yu Chen
Session: Poster Display session 3
Resources:
Abstract